Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated igg displaying high FcγRIIa affinity and selectivity

ACS Chemical Biology

Volumn 8, Issue 2, 2013, Pages 368-375

  Jung, Sang Taek ^a,c   Kelton, William ^a   Kang, Tae Hyun ^a   Ng, Daphne T W ^d   Andersen, Jan Terje ^e,f   Sandlie, Inger ^e,f   Sarkar, Casim A ^d   Georgiou, George ^a,b  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c Kookmin University   (South Korea)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF OSLO   (Norway)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN G; TRASTUZUMAB; ERBB2 PROTEIN, HUMAN; FC RECEPTOR; FC RECEPTOR IIA;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CELL PHAGOCYTOSIS; EFFECTOR CELL; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; MACROPHAGE; MATHEMATICAL MODEL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ENZYME SPECIFICITY; GLYCOSYLATION; METABOLISM; NEOPLASM; PATHOLOGY; PHAGOCYTOSIS; PROTEIN ENGINEERING; TUMOR CELL LINE;

CELL LINE, TUMOR; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN G; NEOPLASMS; PHAGOCYTOSIS; PROTEIN ENGINEERING; RECEPTOR, ERBB-2; RECEPTORS, IGG; SUBSTRATE SPECIFICITY;

EID: 84874101229     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb300455f     Document Type: Article

References (40)

1. Nimmerjahn, F. and Ravetch, J. (2010) Antibody-mediated modulation of immune responses Immunol. Rev. 236, 265-275
2. Smith, K. G. C. and Clatworthy, M. R. (2010) FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications Nat. Rev. Immunol. 10, 328-343
3. Bruhns, P., Iannascoli, B., England, P., Mancardi, D., Fernandez, N., Jorieux, S., and Daeron, M. (2009) Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses Blood 113, 3716-3725
4. Lazar, G., Dang, W., Karki, S., Vafa, O., Peng, J., Hyun, L., Chan, C., Chung, H., Eivazi, A., and Yoder, S. (2006) Engineered antibody Fc variants with enhanced effector function Proc. Natl. Acad. Sci. U.S.A. 103, 4005-4010
5. Stavenhagen, J., Gorlatov, S., Tuaillon, N., Rankin, C., Li, H., Burke, S., Huang, L., Johnson, S., Bonvini, E., and Koenig, S. (2007) Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcγ receptors Cancer Res. 67, 8882-8890
6. Nimmerjahn, F. and Ravetch, J. V. (2005) Divergent immunoglobulin G subclass activity through selective Fc receptor binding Science 310, 1510-1512
7. Rankin, C. T., Veri, M., Gorlatov, S., Tuaillon, N., Burke, S., Huang, L., Inzunza, H. D., Li, H., Thomas, S., and Johnson, S. (2006) CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma Blood 108, 2384-2391
8. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., and Watier, H. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene Blood 99, 754-758
9. Weng, W. K. and Levy, R. (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma J. Clin. Oncol. 21, 3940-3947
10. Shields, R., Namenuk, A., Hong, K., Meng, Y., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., and Li, B. (2001) High resolution mapping of the binding site on human IgG1 for Fcgamma RI, Fcgamma RII, Fcgamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fcgamma R J. Biol. Chem. 276, 6591-6604
11. Umaña, P., Jean-Mairet, J., Moudry, R., Amstutz, H., and Bailey, J. E. (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity Nat. Biotechnol. 17, 176-180
12. Nordstrom, J. L., Gorlatov, S., Zhang, W., Yang, Y., Huang, L., Burke, S., Li, H., Ciccarone, V., Zhang, T., and Stavenhagen, J. (2011) Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fc-gamma receptor binding properties Breast Cancer Res. 13, R123
13. Paz-Ares, L. G., Gomez-Roca, C., Delord, J. P., Cervantes, A., Markman, B., Corral, J., Soria, J. C., Bergé, Y., Roda, D., and Russell-Yarde, F. (2011) Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors J. Clin. Oncol. 29, 3783-3790
14. Zhang, W., Gordon, M., Schultheis, A. M., Yang, D. Y., Nagashima, F., Azuma, M., Chang, H.-M., Borucka, E., Lurje, G., Sherrod, A. E., Iqbal, S., Groshen, S., and Lenz, H.-J. (2007) FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor-expressing metastatic colorectal cancer patients treated with single-agent cetuximab J. Clin. Oncol. 25, 3712-3718
15. Tamura, K., Shimizu, C., Hojo, T., Akashi-Tanaka, S., Kinoshita, T., Yonemori, K., Kouno, T., Katsumata, N., Ando, M., Aogi, K., Koizumi, F., Nishio, K., and Fujiwara, Y. (2011) FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer Ann. Oncol. 22, 1302-1307
16. Yee, A. M. F., Phan, H. M., Zuniga, R., Salmon, J. E., and Musher, D. M. (2000) Association between FcγRIIa-R131 allotype and bacteremic pneumococcal pneumonia Clin. Infect. Dis. 30, 25-28
17. Sanders, L., Feldman, R. G., Voorhorst-Ogink, M. M., de Haas, M., Rijkers, G. T., Capel, P., Zegers, B., and Van de Winkel, J. (1995) Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils Infect. Immun. 63, 73-81
18. Shashidharamurthy, R., Zhang, F., Amano, A., Kamat, A., Panchanathan, R., Ezekwudo, D., Zhu, C., and Selvaraj, P. (2009) Dynamics of the interaction of human IgG subtype immune complexes with cells expressing R and H allelic forms of a low-affinity Fcγ receptor CD32A J. Immunol. 183, 8216-8224
19. Karassa, F. B., Trikalinos, T. A., and Ioannidis, J. P. A. (2002) Role of the Fcγ receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: A meta-analysis Arthritis Rheum. 46, 1563-1571
20. Reilly, A., Norris, C., Surrey, S., Bruchak, F., Rappaport, E., Schwartz, E., and McKenzie, S. (1994) Genetic diversity in human Fc receptor II for immunoglobulin G: Fc gamma receptor IIA ligand-binding polymorphism Clin. Vaccine Immunol. 1, 640-644
21. Sullivan, K., Jawad, A., Piliero, L., Kim, N., Luan, X., Goldman, D., and Petri, M. (2003) Analysis of polymorphisms affecting immune complex handling in systemic lupus erythematosus Rheumatology 42, 446-452
22. Ruffell, B., Au, A., Rugo, H. S., Esserman, L. J., Hwang, E. S., and Coussens, L. M. (2012) Leukocyte composition of human breast cancer Proc. Natl. Acad. Sci. U.S.A. 109, 2796-2801
23. Richards, J., Karki, S., Lazar, G., Chen, H., Dang, W., and Desjarlais, J. (2008) Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells Mol. Cancer Ther. 7, 2517-2527
24. Sazinsky, S., Ott, R., Silver, N., Tidor, B., Ravetch, J., and Wittrup, K. (2008) Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors Proc. Natl. Acad. Sci. U.S.A. 105, 20167-20172
25. Jefferis, R. (2009) Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action Trends Pharmacol. Sci. 30, 356-362
26. Jung, S. T., Reddy, S., Kang, T., Borrok, M., Sandlie, I., Tucker, P., and Georgiou, G. (2010) Aglycosylated IgG variants expressed in bacteria that selectively bind FcγRI potentiate tumor cell killing by monocyte-dendritic cells Proc. Natl. Acad. Sci. U.S.A. 107, 604-609
27. Simmons, L. C., Reilly, D., Klimowski, L., Shantha Raju, T., Meng, G., Sims, P., Hong, K., Shields, R. L., Damico, L. A., Rancatore, P., and Yansura, D. G. (2002) Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies J. Immunol Methods 263, 133-147
28. Krapp, S., Mimura, Y., Jefferis, R., Huber, R., and Sondermann, P. (2003) Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity J. Mol. Biol. 325, 979-989
29. Borrok, M. J., Jung, S. T., Kang, T. H., Monzingo, A. F., and Georgiou, G. (2012) Revisiting the role of glycosylation in the structure of human IgG Fc ACS Chem. Biol. 7, 1596-1602
30. Rhodes, A., Jasani, B., Anderson, E., Dodson, A. R., and Balaton, A. J. (2002) Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors Am. J. Clin. Pathol. 118, 408-417
31. Jung, S. T., Kang, T. H., Kelton, W., and Georgiou, G. (2011) Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy Curr. Opin. Biotechnol. 22, 858-867
32. Stavenhagen, J., Gorlatov, S., Tuaillon, N., Rankin, C., Li, H., Burke, S., Huang, L., Johnson, S., Koenig, S., and Bonvini, E. (2008) Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization Adv. Enzyme Regul. 48, 152-164
33. Harvey, B. R., Georgiou, G., Hayhurst, A., Jeong, K. J., Iverson, B. L., and Rogers, G. K. (2004) Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from Escherichia coli -expressed libraries Proc. Natl. Acad. Sci. U.S.A. 101, 9193-9198
34. Pabbisetty, K. B., Yue, X., Li, C., Himanen, J. P., Zhou, R., Nikolov, D. B., and Hu, L. (2007) Kinetic analysis of the binding of monomeric and dimeric ephrins to Eph receptors: Correlation to function in a growth cone collapse assay Protein Sci. 16, 355-361
35. Hinton, P. R., Xiong, J. M., Johlfs, M. G., Tang, M. T., Keller, S., and Tsurushita, N. (2006) An engineered human IgG1 antibody with longer serum half-life J. Immunol. 176, 346-356
36. Moasser, M. M., Basso, A., Averbuch, S. D., and Rosen, N. (2001) The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells Cancer Res. 61, 7184-7188
37. Reim, F., Dombrowski, Y., Ritter, C., Buttmann, M., Häusler, S., Ossadnik, M., Krockenberger, M., Beier, D., Beier, C. P., Dietl, J., Becker, J. C., Hönig, A., and Wischhusen, J. (2009) Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells Cancer Res. 69, 8058-8066
38. Narayan, M., Wilken, J. A., Harris, L. N., Baron, A. T., Kimbler, K. D., and Maihle, N. J. (2009) Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells Cancer Res. 69, 2191-2194
39. Ramsland, P. A., Farrugia, W., Bradford, T. M., Sardjono, C. T., Esparon, S., Trist, H. M., Powell, M. S., Tan, P. S., Cendron, A. C., Wines, B. D., Scott, A. M., and Hogarth, P. M. (2011) Structural basis for FcγRIIa recognition of human IgG and formation of inflammatory signaling complexes J. Immunol. 187, 3208-3217
40. Indik, Z., Kelly, C., Chien, P., Levinson, A. I., and Schreiber, A. D. (1991) Human Fc gamma RII, in the absence of other Fc gamma receptors, mediates a phagocytic signal J. Clin. Invest. 88, 1766-1771